Eckert & Ziegler (EUZ) Q3 2024 earnings summary

Executive summary

• Revenue for the first nine months of 2024 rose 17% year-over-year to €215.5 million, with FX-adjusted growth at 20% and strong performance in both Medical and Isotope Products segments.

• Medical segment sales grew 26%, Isotope Products up 10%, and radiopharmaceuticals segment up 42%, with robust generator demand, especially in North America.

• Operational cash flow increased 158% to €45.1 million, and cash balance rose 25% to €97.6 million.

• Strategic milestones include European approval for GalliaPharm®, opening of Dresden facility, Pentixapharm spin-off, and a major contract with Telix Pharmaceuticals.

• Headcount increased 7–8% to over 1,100 by end of September.

Financial highlights

• Adjusted EBIT grew 24% year-over-year to €46.7 million, with margin rising to 22% overall, 23% for Medical, and 22% for Isotope Products.

• Gross profit increased to €106.9 million, and EPS from continuing operations reached €1.40 (PY: €1.13).

• Cash and cash equivalents near €98 million, equity ratio at 52%.

• Investments decreased sharply to €1.4 million, and loan liabilities fell to €21.5 million.

• Net income impacted by hyperinflation in Argentina, currency effects, and Pentixapharm spin-off.

Outlook and guidance

• 2024 guidance reaffirmed: expected revenue of €265 million and adjusted EBIT of €55 million.

• Full production capacity booked into next year, with strong order book and no risks threatening ongoing operations.

• Generator business and radiopharmaceuticals expected to remain key growth drivers, with further expansion into Asia and other markets.

• Product mix in Isotope Products expected to weaken in Q4, with full-year gross margin at 2023 levels.